Brooklyn ImmunoTherapeutics (NYSE:BTX) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report released on Monday. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Trading Down 2.7 %

Shares of Brooklyn ImmunoTherapeutics stock opened at $2.16 on Monday. The firm has a fifty day simple moving average of $2.19 and a 200-day simple moving average of $1.80. The stock has a market capitalization of $127.06 million, a price-to-earnings ratio of -0.98 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 1-year low of $0.17 and a 1-year high of $10.10.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.